MEDICINES PATENT POOL
Cancer care can be cheaper: 6 steps to cut drug costs
India has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care, quality checks, cost-effective medicines and pooled procurement to improve affordability.
The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reach
For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that remain out of reach, the affordability crisis runs deep. A proposed cap may help, but question remains if it will be enough to change the picture.
In 1846, Elias Howe patented a lockstitch sewing machine; the patent war around it helped create a licensing model still used in 5G
Elias Howe's journey in the invention of the sewing machine was marked by challenges, as he faced fierce opposition from tailors and struggled with funding. Traveling to England in search of financial support led to a contentious legal battle over his creation. Ultimately, Howe triumphed in court, asserting his rights to the design, a conflict that birthed America's first patent pool, a foundational model that shapes technology licensing paradigms today.
AbbVie loses patent plea for Hep C drug
The Indian Patent Office has denied a secondary patent for AbbVie's Hepatitis C drug Maviret. This decision ensures continued access to affordable treatment for millions. The patent office refused the application after AbbVie failed to contest oppositions and chose to abandon it. This refusal prevents AbbVie from extending its patent monopoly by five years.
Aurobindo to produce, supply long acting HIV treatment drug
Aurobindo Pharma will manufacture and supply long-acting injectable HIV treatment, cabotegravir, across 133 countries through a voluntary licensing agreement. This agreement with Medicines Patent Pool and ViiV Healthcare expands access to an alternative to daily pills, offering injections every one or two months. The move aims to make the advanced treatment widely available and affordable in low and middle-income countries.
Aurobindo Pharma shares rise 3% after subsidiary signs license for generic version of Nilotinib Capsules
Shares of Aurobindo Pharma went up by 3% after the company announced that its subsidiary Eugia Pharma has signed a voluntary license with Medicines Patent Pool to create and market a generic version of Nilotinib Capsules. Aurobindo Pharma’s wholly-owned subsidiary Eugia Pharma Specialities has entered a voluntary sublicensing agreement with Medicines Patent Pool to manufacture and market the drug in 44 low and middle-income countries for the treatment of chronic myeloid leukemia.
- Go To Page 1

Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug
India's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Medicines Patent Pool to develop and market an anti-cancer drug- Nilotinib capsules. Nilotinib capsules are used for the treatment of chronic myeloid leukemia.

Hetero gets WHO prequalification for generic Covid antiviral Paxlovid
This is the first WHO prequalification for Paxlovid - a combination of nirmatrelvir and ritonavir which is recommended for treating mild and moderate Covid patients at the highest risk of hospital admissions, such as unvaccinated, aged, or immunosuppressed patients.

Zenara Gets Nod to Manufacture, Sell Pfizer's Paxlovid
The company said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment option for patients with mild to moderate symptoms of Covid-19. While the price of medicine is yet to be decided, it will be manufactured at Zenara's USFDA-approved state-of-the-art facility in Hyderabad.

Zenara pharma to launch generic Paxlovid soon
The company said that Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of Covid-19 will be available soon.

19 Indian companies get licence to make Pfizer's oral generic
These include Cipla, Sun Pharma, Laurus Labs, Divi's Laboratories, Glenmark, Emcure, Macleods, SMS Pharmaceuticals, Strides, Torrent, Cadila, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, and Viatris, among others.

Torrent & Cadila Pharmaceuticals get license to manufacture oral antiviral Covid-19 pill nirmatrelvir
Torrent said that t it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with MPP. Cadila said that it will cater to Indian and export markets since many countries with high Covid-19 burden lack access to effective therapy.

Torrent & Aurobindo receive licenses to sell Pfizer's COVID pill Paxlovid in India, low income countries
The oral COVID-19 treatment comprises of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations.

Biophore India receives licences from MPP to market molnupiravir
The licences are applicable for both active pharmaceutical ingredients (API) and finished product in capsules form. It enables the company to launch the product within India as well as export to 104 other countries around the world, Biophore India Pharmaceuticals said in a statement.

Natco Pharma signs pact with MPP to sell Molnupiravir capsules
Natco Pharma has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupiravir capsules 200 mg for treatment of COVID-19. MPP had taken licence from Merck Sharp & Dohme Corp (MSD), USA for the same, the company said

MSD enters pact with UN-backed MPP to license COVID drug molnupiravir in 105 countries including India
Under the terms of the agreement, MPP will be permitted to further license non-exclusive sub-licences to manufacturers and diversify the manufacturing base for the supply of quality-assured or WHO-prequalified molnupiravir to countries covered by the MPP Licence.

MSD in talks with Medicines Patent Pool for additional licenses for molnupiravir
MSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddy’s, Emcure and Hetero for molnupiravir, an experimental drug that is currently tested to treat Covid-19 infections. Merck is running the clinical trials for molnupiravir with its partner Ridgeback Biotherapeutics.

MSD to sign licensing pacts with 5 Indian drug firms for oral drug candidate for COVID-19
MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufacturers -- Cipla, Dr Reddy's Laboratories, Emcure Pharmaceuticals, Hetero Labs and Sun Pharmaceutical Industries, it added.

Bilateral deals might not be equitable for Covid-19: MPP executive director Charles Gore
The Medicines Patent Pool is a United Nations-backed public health organisation that helps middle- and low-income countries get access to critical drugs. MPP executive director Charles Gore told ET’s Divya Rajagopal about the organisation’s plan to ensure equitable access of Covid-19 drugs and vaccines.

Cadila Healthcare jumps 5% as drugmaker inks pact for Hepatitis C tablets
The agreement sub-licenses Zydus to produce and sell daclatasvir in 112 low and middle income countries, it added.

Zydus Cadila inks pact with Medicines Patent Pool for Hepatitis C drug
Between 130 and 150 million people worldwide are estimated to have HCV. The vast majority lives in low and middle income countries, it added.

Natco Pharma signs agreement for manufacturing, sale of hepatitis C drug
Daclatasvir, discovered and developed by Bristol-Myer Squibb, is the first-in-class NS5A inhibitor used in combination with Sofosbuvir to treat patients with chronic hepatitis C virus (HCV) genotype 3 infect

Cipla, Emcure, Hetero and Natco Pharma join patent pool for new Hepatitis C drug Daclatavir
There might be more companies who might join the patent pool for the drug. Daclatasvir is known to cure multiple genotypes of the Hep C virus.

Cipla, Aurobindo, Emcure to supply HIV drugs for UN-backed programme
Aurobindo Pharma Chief Executive Officer said the new licence would help ensure the timely introduction of generic ATV in developing countries.

Shilpa Medicare inks pact with MPP, Gilead for HIV/AIDS drugs
Shilpa Medicare inked an agreement with Gilead Sciences to increase access to medicines used for treatment of HIV/AIDS.

CCI rules out case against Gilead Sciences
CCI has rejected a complaint against Gilead Sciences Inc that alleged the US-based pharmaceutical company of abusing its dominant position.
Hetero Labs to produce Gilead's HIV drugs, through Medicines Patent Pool
Hyderabad based Hetero labs through an agreement with Geneva based Medicines Patent Pool will produce four key HIV drugs developed by Gilead Lifesciences.
Big pharma companies must allow generic firms to sell cheap HIV drugs to poor nations
An independent mechanism that protects the patent rights of Big Pharma while allowing generic firms to sell cheap, copycat HIV drugs to poor countries.
Gilead Sciences Inc allows 4 Indian pharmaceutical companies Ranbaxy Laboratories, Matrix Laboratories, Hetero Drugs and Strides Arcolab to sell HIV Generics
Ranbaxy Laboratories, Matrix Laboratories, Hetero Drugs and Strides Arcolab can make and sell the three drugs in 100 countries by paying royalty.
Load More